A subsequent open-label, single-treatment arm study failed to show a clinical benefit in patients suffering from ATTRv with polyneuropathy with the Val30Met mutation and an advanced disease stage at the time of treatment initiation, thus showing the importance of starting pharmacological stabilization of TTR tetramers at earlier disease stages [104]. The gene discussed is TTR; the disease is polyneuropathy.